Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 525-535

  Tentori, Lucio ^a   Vergati, Matteo ^a   Muzi, Alessia ^a   Levati, Lauretta ^a   Ruffini, Federica ^b   Forini, Olindo ^a   Vernole, Patrizia ^a   Lacal, Pedro Miguel ^a   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

Author keywords

Angiogenesis; Endothelial cells; Immortalization; Poly(ADP ribose) polymerase; Telomerase; Temozolomide; Tumor endothelial markers

Indexed keywords

ALKYLATING AGENT; CD164L1 PROTEIN, HUMAN; CD31 ANTIGEN; DACARBAZINE; DNA BINDING PROTEIN; DRUG DERIVATIVE; FLT1 PROTEIN, HUMAN; MEMBRANE PROTEIN; TELOMERASE; TEMOZOLOMIDE; TUMOR PROTEIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS T ANTIGEN; VON WILLEBRAND FACTOR;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; CELL PROLIFERATION; CELL STRAIN HT29; CELL TRANSFORMATION; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIGENS, CD31; ANTIGENS, POLYOMAVIRUS TRANSFORMING; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL LINE; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DACARBAZINE; DNA-BINDING PROTEINS; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GENE EXPRESSION; HT29 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 33644693775     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.525     Document Type: Article

References (64)

1. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997.
2. Kerbel R and Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739, 2002.
3. Shimizu K and Oku N: Cancer anti-angiogenic therapy. Biol Pharm Bull 27: 599-605. 2004.
4. Oku N: Anticancer therapy using glucuronate modified long-circulating liposomes. Adv Drug Dcliv Rev 40: 63-73. 1999.
5. Schirner M. Hoffmann J. Mcnrad A and Schneider MR: Anti-angiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 4: 1331-1336. 1998.
6. Browder T. Butterfield CE. Kraling BM. Shi B. Marshall B. O'Reilly MS and Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
7. Klement G, Baruchel S. Rak J. Man S, Clark K. Hicklin DJ. Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000.
8. Teifel M and Friedl P: Establishment of the permanent micro-vascular endothelial cell line PBMEC/CI-2 from porcine brains. Exp Cell Res 228: 50-57. 1996.
9. Schulz M. Teifel M and Friedl P: Establishment of a human placental endothelial cell line with extended life span after transfection with SV 40 T-antigens. Eur J Cell Biol 74: 315-320. 1997.
10. Stins MF. Prasadarao NV. Zhou J. Arditi M and Kim KS: Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development or an immortalized cell line to study pathophysiology of CNS disease. In vitro Cell Dev Biol Anim 33: 243-247. 1997.
11. Duncan EL. Wadhwa R and Kaul SC: Senescence and immortalization of human cells. Biogerontology I: 103-121,2000.
12. Shay JW. van Der Haegen BA. Ying Y and Wright WE: The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209: 45-52. 1993.
13. Counter CM, Avilion AA, Le Feuvre CE. Stewart NG. Grcider CW. Harley CB and Baechetti S: Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921-1929. 1992.
14. Harley CB. Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460. 1990.
15. Cech TR: Beginning to understand the end of the chromosome. Cell 116: 273-279, 2004.
16. Bodnar AG. Ouellette M. Frolkis M. Holt SE, Chiu CP. Morin GB. Harley CB. Shay JW, Lichtsteiner S and Wright WE: Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352. 1998.
17. Jiang XR. Jimenez G, Chang E, Frolkis M. Kusler B. Sage M. Beeche M. Bodnar AG. Wahl GM. Tlsty TD and Chiu CP: Telomerase expression in human somatic cells docs not induce changes associated with a transformed phenotype. Nat Genet 21: 111-114. 1999.
18. Morales CP. Holt SE. Ouellette M. Kaur KJ, Yan Y. Wilson KS. White MA, Wright WE and Shay JW: Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21: 115-118. 1999.
19. Yang J. Chang E, Cherry AM, Bangs CD. Oei Y. Bodnar A. Bronstein A. Chiu CP and Herron GS: Human endothelial cell life extension by telomerase expression. J Biol Chem 274: 26141-26148. 1999.
20. Kiyono T. Foster SA, Koop Jl. McDougall JK, Galloway DA and Klingelhutz AJ: Both Rb/p161NK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396: 84-88. 1998.
21. Gagnon E, Cattaruzzi P. Griffith M. Muzakare L. Le Flao K. Faure R. Beliveau R. Hussain SN. Kouisilieris M and Doillon CJ: Human vascular endothelial cells with extended life spans: in vitro cell response, protein expression, and angiogenesis. Angio-genesis 5: 21-33, 2002.
22. Gu X. Zhang J, Brann DW and Yu FS: Brain and retinal vascular endothelial cells with extended life span established by ectopic expression of telomerase. Invest Ophthalmol Vis Sci 44: 3219-3225.2003.
23. Nisato RE. Harrison JA. Buser R. Orci L. Rinsch C. Montesano R. Dupraz P and Pepper MS: Generation and characterization of telomerase-transfeeted human lymphatic endothelial cells with an extended life span. Am J Pathol 165: 11-24. 2004.
24. Orecchia A. Lacal PM. Schietroma C. Morea V. Zambrano G and Failla CM: Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta I integrin. J Cell Sci 116: 3479-3489. 2003.
25. Litzkas P. Jha KK and Ozer HL: Efficient transfer of cloned DNA into human diploid cells: protoplast fusion in suspension. Mol Cell Biol 4: 2549-2552. 1984.
26. Hahn WC. Stewart SA. Brooks MW. York SG. Eaton E. Kurachi A. Beijersbergen RL. Knoll JH. Meyerson M and Weinberg RA: Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5: 1164-1170. 1999.
27. Piatyszek MA. Kim NW. Weinrich SL. Hiyama K. Hiyama E. Wright WE and Shay JW: Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17: 1-15. 1995.
28. Tentori L. Turriziani M. Franco D. Serafino A, Levali L. Roy R. Bonmassar E and Graziani G: Treatment with temozolomidc and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13: 901-909. 1999.
29. Jin H and Varner J: Integrins: roles in cancer development and as treatment targets. Br J Cancer 90: 561-565. 2004.
30. Brooks PC. Clark RA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571. 1994.
31. St Croix B. Rago C. Velculescu V. Traverso G. Romans KE. Montgomery E. Lal A. Riggins GJ. Lengauer C. Vogelstein B and Kinzlcr KW: Genes expressed in human tumor endothelium. Science 289: 1197-1202. 2000.
32. Nanda A and St Croix B: Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 16: 44-49. 2004.
33. Burrows FJ. Derbyshire EJ. Tazzari PL. Amlot P. Gazdar AF. King SW. Letarte M. Vitetta ES and Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634. 1995.
34. Miller DW. Graulich W, Karges B, Stahl S. Ernst M. Ramaswamy A. Sedlacek HH. Muller R and Adamkiewicz J: Elevated expression of endoglin. a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81: 568-572. 1999.
35. Tentori L. Portarena I. Bonmassar E and Graziani G: Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomidc and poly(ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-profilerating tumor cells. Cell Death Differ 8: 457-469. 2001.
36. Tentori L, Portarena I. Vernole P. Gold B and Graziani G: Apoptotic and genotoxie effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother Pharmacol 49: 217-224. 2002.
37. Tentori L. Portarena I. Barbarino M. Balduzzi A. Levati L. Vergati M. Biroccio A. Gold B. Lombardi ML and Graziani G: Inhibition of telomerase increases resistance of melanoma cells to temozolomide. but not to temozolomidc combined with polyl ADP-ribosc) polymerase inhibitor. Mol Pharmacol 63: 192-202. 2003.
38. Tentori L. Leonetti C. Scarsella M. D'Amati G, Portarena I, Zupi G, Bonmassar E and Graziani G: Combined treatment with temozolomidc and polyl ADP-ribosc) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99: 2241-2244. 2002.
39. Tentori L. Leonetti C. Scarsella M. D'Amati G. Vergati M. Portarena I. Xu W. Kalish V. Zupi G. Zhang J and Graziani G: Systemic administration of GPI 15427. a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomidc against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9: 5370-5379. 2003.
40. Miknyoczki SJ. Joncs-Bolin S. Pritchard S. Hunter K. Zhao H. Wan W, Ator M. Bihovsky R. Hudkins R. Chatterjee S. Klein-Szamo A. Dionne C and Ruggeri B: Chemopotentiation of tcmozolomidc. irinotecan. and cisplalin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382. 2003.
41. Krump-Konvalinkova V, Bittinger F. Unger RE. Peters K. Lehr HA and Kirkpatrick CJ: Generation of human pulmonary microvascular endothelial cell lines. Lab Invest 81: 1717-1727. 2001.
42. Bouis D. Hospers GA, Meijer C. Molema G and Mulder NH: Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 4: 91-102. 2001.
43. Matsumura T, Takesue M. Weslerman KA. Okitsu T. Sakaguchi M. Fukazawa T. Totsugawa T. Noguchi H. Yamamoto S. Stolz DB. Tanaka N. Leboulch P and Kobayashi N: Establishment of an immortalized human-liver endothelial cell line with SV40T and hTERT. Transplantation 77: 1357-1365. 2004.
44. Shay JW, Pereira-Smith OM and Wright WE: A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 196: 33-39. 1991.
45. O'Hare MJ. Bond J, Clarke C. Takeuchi Y, Atherton AJ. Berry C. Moody J, Silver AR. Davies DC. Alsop AE. Neville AM and Jat PS: Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci USA 98:646-651.2001.
46. Venetsanakos E. Mirza A. Fanton C. Romanov SR, Tlsty T and McMahon M: Induction of tubulogenesis in telomerase-immonalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 273: 21-33. 2002.
47. Freedman DA and Folkman J: Maintenance of G1 checkpoint controls in telomerase-immortalized endothelial cells. Cell Cycle 3:811-816, 2004.
48. Rettig WJ. Garin-Chesa P. Healey JH. Su SL, Jaffe EA and Old LJ: Identification of endosialin. a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836. 1992.
49. Carson-Walter EB, Watkins DN, Nanda A. Vogelstein B. Kinzter KW and St Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61: 6649-6655.2001.
50. Opavsky R. Haviernik P. Jurkovicova D. Garin MT. Copeland NG. Gilbert DJ. Jenkins NA. Bies J. Garfield S. Pastorekova S. Oue A and Wolff L: Molecular characterization of the mouse Teml/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 276: 38795-38807, 2001.
51. Gaya A, Rees J, Greenstein A and Stebbing J: The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28: 115-120.2002.
52. Quinn JA. Reardon DA. Friedman AH. Rich JN. Sampson JH. Provenzale JM. McLendon RE. Gururangan S. Bigner DD. Herndon JE II. Avgeropoulos N. Finlay J. Tourt-Uhlig S. Affronti ML. Evans B. Stafford-Fox V. Zaknoen S and Friedman HS: Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21: 646-651.2003.
53. Abrey LE and Christodoulou C: Temozolomide for treating brain metastases. Semin Oncol 28: 34-42. 2001.
54. Seiter K. Liu D. Loughran T. Siddiqui A. Baskind P and Ahmed T: Phase I study of temozolomide in relapsed/refractory acute leukaemia. J Clin Oncol 20: 3249-3253. 2002.
55. Reni M. Ferreri AJ. Landoni C and Villa E: Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92: 575-576. 2000.
56. Middleton MR. Grob JJ. Aaronson N. Fierlbeck G. Tilgen W, Seiter S. Gore M. Aamdal S. Cebon J. Coates A. Dreno B. Henz M. Schadendorf D. Kapp A. Weiss J. Fraass U, Statkevich P. Muller M and Thatcher N: Randomized phase III study of temozolomide versus dacarbazinc in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18: 158-166.2000.
57. Newlands ES. Stevens MF. Wedge SR. Wheelhouse RT and Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61. 1997.
58. D'Atri S. Tentori L. Local PM. Graziani G. Pagani E. Benincasa E. Zambruno G. Bonmassar E and Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 54: 334-341. 1998.
59. Hirose Y. Berger MS and Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61: 1957-1963. 2001.
60. Kurzen H. Schmitt S. Naher H and Mohler T: Inhibition of angiogenesis by non-toxic doses of tcmozolomidc. Anticancer Drugs 14: 515-522. 2003.
61. Shin KH. Kang MK. Dieterow E. Kameta A. Baluda MA and Park NH: Introduction of human telomerase reverse transcriptase to normal human fibroblasts enhances DNA repair capacity. Clin Cancer Res 10: 2551-2560. 2004.
62. Tentori L and Graziani G: Pharmacological strategics to increase the antitumor activity of methylating agents. Curr Med Chem 9: 1285-1301.2002.
63. Tentori L and Graziani G: Temozolomide: an update on pharmacological strategies to increase its antitumor activity. Med Chem Rev-Online 1: 144-150. 2004.
64. Tentori L and Graziani G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; doi: 10.1016/ j.phrs.2005.02.010.